Marcelo V. Negrao,Haniel A. Araujo,Giuseppe Lamberti,Alissa J. Cooper,Neal S. Akhave,Teng Zhou,Lukas Delasos,J. Kevin Hicks,Mihaela Aldea,Gabriele Minuti,Jacobi Hines,Jacqueline V. Aredo,Michael J. Dennis,Turja Chakrabarti,Susan C. Scott,Paolo Bironzo,Matthias Scheffler,Petros Christopoulos,Albrecht Stenzinger,Jonathan W. Riess,So Yeon Kim,Sarah B. Goldberg,Mingjia Li,Qi Wang,Yun Qing,Ying Ni,Minh Truong Do,Richard Lee,Biagio Ricciuti,Joao Victor Alessi,Jing Wang,Blerina Resuli,Lorenza Landi,Shu-Chi Tseng,Mizuki Nishino,Subba R. Digumarthy,Waree Rinsurongkawong,Vadeerat Rinsurongkawong,Ara A. Vaporciyan,George R. Blumenschein,Jianjun Zhang,Dwight H. Owen,Collin M. Blakely,Giannis Mountzios,Catherine A. Shu,Christine M. Bestvina,Marina Chiara Garassino,Kristen A. Marrone,Jhanelle E. Gray,Sandip Pravin Patel,Amy L. Cummings,Heather A. Wakelee,Juergen Wolf,Giorgio Vittorio Scagliotti,Federico Cappuzzo,Fabrice Barlesi,Pradnya D. Patil,Leylah Drusbosky,Don L. Gibbons,Funda Meric-Bernstam,J. Jack Lee,John V. Heymach,David S. Hong,Rebecca S. Heist,Mark M. Awad,Ferdinandos Skoulidis

Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Fig S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplementary Materials and Methods from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Figure S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Supplementary Table S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Methods and Data (posted 7/5/2011) from Characterization of <i>KRAS</i> Rearrangements in Metastatic Prostate Cancer

Supplementary Figure S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Information from A Combinatorial Strategy for Targeting &Lt;i>braf</i><sup>v600e</sup>-Mutant Cancers with BRAF<sup>V600E</sup> Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)

Supplemental Material and Methods from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Supplementary Figure 1 from Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Supplementary Materials and Methods from Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>bap1</i> and <i>setd2</i>: A Report by MSKCC and the KIRC TCGA Research Network

Supplementary Figure S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Table S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Supplementary Methods from AZ1366: an Inhibitor of Tankyrase and the Canonical Wnt Pathway That Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Figure S10 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Methods, Figures S1 - S14, Tables S1, S3 - S10 from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling

Supplementary Materials and Methods from <i>pik3ca</i> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Fig S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplementary Materials and Methods from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Figure S2 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Supplementary Table S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Methods and Data (posted 7/5/2011) from Characterization of &lt;i&gt;KRAS&lt;/i&gt; Rearrangements in Metastatic Prostate Cancer

Supplementary Figure S2 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC

Supplementary Information from A Combinatorial Strategy for Targeting &Lt;i&gt;braf&lt;/i&gt;&lt;sup&gt;v600e&lt;/sup&gt;-Mutant Cancers with BRAF&lt;sup&gt;V600E&lt;/sup&gt; Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)